AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Science, Spoken
The Race for the Next Ozempic
Jul 25, 2024
Pharmaceutical companies are in a race to develop innovative obesity drugs like GLP-1 receptor agonists. These drugs have the potential to help with weight loss and reshape the obesity treatment market.
09:22
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP-1 drugs aid weight loss by controlling blood sugar and appetite suppression.
- Pharma companies are developing new anti-obesity medications targeting GLP-1 and GIP receptors.
Deep dives
Development of GLP-1 Receptor Agonists for Weight Loss
The discovery of the hormone GLP-1 in the 1980s led to the development of GLP-1 receptor agonists, such as Saxenda and Ozempic, for weight loss. These drugs not only help control blood sugar but also have the side effect of suppressing appetite, leading to weight loss. Recent advancements include newer drugs like Terzepatide and Rediutide, which have shown significant weight loss results in trials.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode